Lannett Company, Inc.
Lannett Company, Inc. (United States) holds 0 active US FDA Type II Drug Master Files and 1 inactive. 41 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Lannett Company, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/lannett-company-inc
Overview
Lannett Company, Inc. is a pharmaceutical company that develops, manufactures, and sells generic medications. The company focuses on producing affordable alternatives to branded drugs, covering a range of therapeutic areas. Lannett is committed to delivering quality health products while fostering innovation in the pharmaceutical industry.
Core services & business areas
API / Drug Master Files
Lannett Company, Inc. holds 0 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES.Inactive1970-11-24
FDA compliance signals
41 FDA enforcement records linked to this company.
- recall — Class II2026-07-08
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.
- recall — Class II2026-06-10
Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.
- recall — Class III2026-05-27
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
- recall — Class II2025-10-29
Failed Dissolution Specifications
- recall — Class II2025-09-17
Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct, contained one (1) tablet of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 5 mg.
- recall — Class II2025-09-03
Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.
- recall — Class II2024-12-11
Failed Content Uniformity Specifications: Product failed to meet the action limits for stratified content uniformity.
- recall — Class III2023-01-25
Failed Impurity/Degradation Specifications
- recall — Class III2023-01-25
Failed Impurity/Degradation Specifications
- recall — Class II2022-02-23
Failed Impurities/Degradation Specifications: Out of specification results for related substances.
- recall — Class II2020-08-26
Labeling: Label Mix Up: bottle labeled to contain Prednisone Tablets, USP 2.5 mg actually contained Prednisone Tablets, USP 10 mg
- recall — Class I2019-12-25
Microbial Contamination of Non-sterile Products: Out-of-specification results obtained for Total Aerobic Microbial Count.
- recall — Class II2019-11-20
CGMP Deviations: Presence of NDMA impurity detected in product.
- recall — Class III2019-03-20
Failed Dissolution Specifications
- recall — Class II2018-10-31
CGMP Deviations: cleaning procedures during manufacturing caused out of specification results for unknown impurities.
- 4832018-02-02
Batch production and Batch Control Record Requirements
- 4832018-02-02
Procedures not in writing, fully followed
- 4832012-10-31
Extent of discrepancy, failure investigations
- 4832012-10-31
Procedures not in writing, fully followed
- 4832012-10-31
Acceptance criteria for sampling & testing
- 4832012-10-31
Calibration/Inspection/Checking not done
- 4832012-10-31
Equipment Design, Size and Location
- 4832012-10-31
Complaint Handling Procedure
- 4832011-05-13
Sanitation--buildings not clean, free of infestation
- 4832011-05-13
Identification of containers, lines, equipment
- 4832011-03-21
Buildings of Suitable Size, Construction, Location
- 4832011-03-21
Written procedures not established/followed
- 4832011-03-21
Complaint Handling Procedure
- 4832011-03-21
Establishment of time limitations
- 4832011-03-21
Absence of Written Procedures
- 4832011-03-21
Defined areas of adequate size for operations
- 4832011-03-21
Investigations of discrepancies, failures
- 4832010-02-09
Extent of discrepancy, failure investigations
- 4832010-02-09
Absence of Written Procedures
- 4832010-02-09
Record information inclusions
- 4832010-02-09
Rejected Material Area
- 4832010-02-09
Investigations of discrepancies, failures
- 4832010-02-09
Control procedures to monitor and validate performance
- 4832010-02-09
Returned drug procedures in writing and followed
- 4832010-02-09
Associated batches implicated, investigated
- warning_letter2009-03-30
FDA Warning Letter (drug product)
Is this Lannett Company, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.